Atlas Trials

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT07529782 · RECRUITING

Trial details

NCT number
NCT07529782
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma and Other Plasma Cell Neoplasms
Start date
2026-03-17
Primary completion
2026-06-30
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.